ID
42960
Description
see http://clinicaltrials.gov/ct2/show/study/NCT00048295 ISIS 2302 is an antisense oligonucleotide drug that reduces the production of a specific protein called intercellular adhesion molecule (ICAM-1), a substance that plays a significant role in the increase of inflammation. People with Crohn’s disease have been shown to over-produce ICAM-1 in their gut tissues. Alicaforsen works by blocking ICAM-1 messenger RNA, the “instruction” molecule that is required for the production of ICAM-1 protein. This trial will examine effects of alicaforsen delivered by 2-hour intravenous infusion over a four-week period, compared to a placebo. Patients may remain on stable background 5-ASA, antibiotic, or immunosuppressive drugs, and prednisone (or equivalent) at </= 30 mg per day.
Link
http://clinicaltrials.gov/ct2/show/study/NCT00048295
Keywords
Versions (4)
- 11/14/11 11/14/11 -
- 11/14/11 11/14/11 -
- 3/22/14 3/22/14 - Martin Dugas
- 9/17/21 9/17/21 -
Uploaded on
September 17, 2021
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility NCT00048295 Crohns Disease
Eligibility NCT00048295
- StudyEvent: Eligibility
Description
Exclusion
Description
Severe intestinal stenosis
Data type
boolean
Alias
- UMLS CUI-1
- C0521587
Description
External fistulization
Data type
boolean
Alias
- UMLS CUI-1
- C0016169
Description
Infection
Data type
boolean
Alias
- UMLS CUI-1
- C0009450
Description
Malignancy
Data type
boolean
Alias
- UMLS CUI-1
- C0006826
Description
Bleeding problem
Data type
boolean
Alias
- UMLS CUI-1
- C1458140
Similar models
Eligibility NCT00048295
- StudyEvent: Eligibility
C1456820 (UMLS CUI-2)
C0021469 (UMLS CUI-3)